Guidelines 2.0: do no net harm-the future of practice guideline development in asthma and other diseases.
about
Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development?The role of group decision making processes in the creation of clinical guidelines.Deciding what type of evidence and outcomes to include in guidelines: article 5 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
P2860
Guidelines 2.0: do no net harm-the future of practice guideline development in asthma and other diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidelines 2.0: do no net harm ...... in asthma and other diseases.
@en
Guidelines 2.0: do no net harm ...... in asthma and other diseases.
@nl
type
label
Guidelines 2.0: do no net harm ...... in asthma and other diseases.
@en
Guidelines 2.0: do no net harm ...... in asthma and other diseases.
@nl
prefLabel
Guidelines 2.0: do no net harm ...... in asthma and other diseases.
@en
Guidelines 2.0: do no net harm ...... in asthma and other diseases.
@nl
P2860
P1476
Guidelines 2.0: do no net harm ...... in asthma and other diseases.
@en
P2093
Holger J Schünemann
P2860
P2888
P304
P356
10.1007/S11882-011-0185-8
P577
2011-06-01T00:00:00Z